Navigation Links
Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology
Date:5/24/2013

Madison, WI (PRWEB) May 24, 2013

Quincy Bioscience, a leading research company committed to the discovery and development of calcium-binding proteins to support healthy living, is pleased to announce publication of safety assessment study of apoaequorin in Food and Chemical Toxicology, an international journal published for the British Industrial Biological Research Association.

The objective of the study was to investigate potential adverse effects, if any, of apoaequorin, in rats following subchronic administration. Based on the results of this study, the No Observed-Adverse-Effect Level (NOAEL) for apoaequorin was determined as 666.7 mg/kg bw/day, the highest dose tested. Administration of the apoaequorin preparation did not result in any mortality. There were no further clinical or opthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology, or histopathological changes attributable to administration of apoaequorin.

Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health. Apoaequorin is included in the dietary supplement Prevagen. It is used to improve mild memory loss associated with aging.

To get more information on the study, please visit the journal of Food and Chemical Toxicology. To get more information on apoaequorin, please visit the Prevagen website.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10765048.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
2. New measuring techniques can improve efficiency, safety of nanoparticles
3. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
4. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
5. Notre Dame paper examines nanotechnology-related safety and ethics problem
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
10. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
11. Produce Safety Researchers Awarded by ABC Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Church, VA (PRWEB) , ... ... ... first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes place ... PA. The two-day event features 20+ speakers and activities such as workshops ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... --> --> ... pleased to provide the following update on recent corporate developments. ... last 3 months we have significantly increased our cash position ... As a result, we have positioned ourselves to execute on ... and expect that development to continue on schedule. ...
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):